RGMP Stock Overview
Develops and commercializes therapeutics that treat rare and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Regnum Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.014 |
| 52 Week Low | US$0.000001 |
| Beta | 2.63 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| RGMP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -0.8% | 1.8% |
| 1Y | n/a | 22.3% | 31.9% |
Return vs Industry: Insufficient data to determine how RGMP performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how RGMP performed against the US Market.
Price Volatility
| RGMP volatility | |
|---|---|
| RGMP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RGMP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RGMP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 2 | n/a | n/a |
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C—C chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company was incorporated in 2016 and is based in New York, New York.
Regnum Corp. Fundamentals Summary
| RGMP fundamental statistics | |
|---|---|
| Market cap | US$22.00 |
| Earnings (TTM) | -US$693.70k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs RGMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGMP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$693.71k |
| Earnings | -US$693.70k |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.03 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -115.9% |
How did RGMP perform over the long term?
See historical performance and comparison